FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2157385885> ?p ?o ?g. }

• W2157385885 endingPage "1648" @default.
• W2157385885 startingPage "1648" @default.
• W2157385885 abstract "Recent findings of increased cathelicidin protein and its proteolytic fragments in rosacea suggest a pathogenic role for cathelicidin in this disease. The relationship between cathelicidin and protease-activated receptor 2 (PAR-2) is therefore of interest, as PAR-2, expressed principally in keratinocytes, regulates pro-inflammatory cytokine expression in the skin. The purpose of this study was to determine the relationship between expression of PAR-2 and cathelicidin in rosacea and to test the effect of direct PAR-2 activation on cathelicidin expression in keratinocytes.Samples from 40 patients with clinicopathologic diagnosis of rosacea and facial skin tissue samples from 20 patients with no specific findings or milium without inflammation were retrieved. Intensities of immunohistochemical staining for PAR-2 and cathelicidin were compared between normal and rosacea-affected skin tissues. Additionally, correlations between PAR-2 and cathelicidin staining intensities within rosacea patients were analyzed. In cultured keratinocytes, changes in PAR-2, cathelicidin, and vascular endothelial growth factor (VEGF) mRNA and protein were analyzed after treatment with PAR-2 activating peptide (AP).Cathelicidin expression was significantly higher in rosacea skin tissues than in normal tissues (p<0.001), while PAR-2 expression was not significantly higher in rosacea tissues than in normal skin tissues. A positive correlation between PAR-2 and cathelicidin within rosacea samples was observed (R=0.330, p=0.037). After treatment of PAR-2 AP, both mRNA and protein levels for PAR-2, cathelicidin, and VEGF significantly increased in cultured keratinocytes, compared with PAR-2 control peptide treatment.PAR-2 may participate in the pathogenesis of rosacea through activation of cathelicidin LL-37, a mediator of innate immune responses in the skin." @default.
• W2157385885 created "2016-06-24" @default.
• W2157385885 creator A5007119006 @default.
• W2157385885 creator A5007873429 @default.
• W2157385885 creator A5027267389 @default.
• W2157385885 creator A5037846990 @default.
• W2157385885 creator A5056400066 @default.
• W2157385885 creator A5084234477 @default.
• W2157385885 date "2014-01-01" @default.
• W2157385885 modified "2023-09-30" @default.
• W2157385885 title "Increased Expression of Cathelicidin by Direct Activation of Protease-Activated Receptor 2: Possible Implications on the Pathogenesis of Rosacea" @default.
• W2157385885 cites W1587261904 @default.
• W2157385885 cites W1647699403 @default.
• W2157385885 cites W1921818371 @default.
• W2157385885 cites W1964758221 @default.
• W2157385885 cites W1966298489 @default.
• W2157385885 cites W1969969289 @default.
• W2157385885 cites W1977160855 @default.
• W2157385885 cites W1979258089 @default.
• W2157385885 cites W1979267735 @default.
• W2157385885 cites W1980269992 @default.
• W2157385885 cites W1991620958 @default.
• W2157385885 cites W1992681571 @default.
• W2157385885 cites W2001544048 @default.
• W2157385885 cites W2004697420 @default.
• W2157385885 cites W2016702197 @default.
• W2157385885 cites W2025374951 @default.
• W2157385885 cites W2028554852 @default.
• W2157385885 cites W2036402516 @default.
• W2157385885 cites W2038481829 @default.
• W2157385885 cites W2041560508 @default.
• W2157385885 cites W2043804545 @default.
• W2157385885 cites W2045389117 @default.
• W2157385885 cites W2053870595 @default.
• W2157385885 cites W2064016804 @default.
• W2157385885 cites W2064575751 @default.
• W2157385885 cites W2065273951 @default.
• W2157385885 cites W2068698172 @default.
• W2157385885 cites W2069492069 @default.
• W2157385885 cites W2069767465 @default.
• W2157385885 cites W2070431811 @default.
• W2157385885 cites W2083772421 @default.
• W2157385885 cites W2087943501 @default.
• W2157385885 cites W2092853938 @default.
• W2157385885 cites W2096971083 @default.
• W2157385885 cites W2117618216 @default.
• W2157385885 cites W2142461098 @default.
• W2157385885 cites W2149169307 @default.
• W2157385885 cites W2150732175 @default.
• W2157385885 cites W2163902606 @default.
• W2157385885 doi "https://doi.org/10.3349/ymj.2014.55.6.1648" @default.
• W2157385885 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4205707" @default.
• W2157385885 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25323904" @default.
• W2157385885 hasPublicationYear "2014" @default.
• W2157385885 type Work @default.
• W2157385885 sameAs 2157385885 @default.
• W2157385885 citedByCount "25" @default.
• W2157385885 countsByYear W21573858852015 @default.
• W2157385885 countsByYear W21573858852016 @default.
• W2157385885 countsByYear W21573858852017 @default.
• W2157385885 countsByYear W21573858852018 @default.
• W2157385885 countsByYear W21573858852019 @default.
• W2157385885 countsByYear W21573858852020 @default.
• W2157385885 countsByYear W21573858852021 @default.
• W2157385885 countsByYear W21573858852022 @default.
• W2157385885 countsByYear W21573858852023 @default.
• W2157385885 crossrefType "journal-article" @default.
• W2157385885 hasAuthorship W2157385885A5007119006 @default.
• W2157385885 hasAuthorship W2157385885A5007873429 @default.
• W2157385885 hasAuthorship W2157385885A5027267389 @default.
• W2157385885 hasAuthorship W2157385885A5037846990 @default.
• W2157385885 hasAuthorship W2157385885A5056400066 @default.
• W2157385885 hasAuthorship W2157385885A5084234477 @default.
• W2157385885 hasBestOaLocation W21573858851 @default.
• W2157385885 hasConcept C136449434 @default.
• W2157385885 hasConcept C16005928 @default.
• W2157385885 hasConcept C203014093 @default.
• W2157385885 hasConcept C204232928 @default.
• W2157385885 hasConcept C2777379352 @default.
• W2157385885 hasConcept C2777673923 @default.
• W2157385885 hasConcept C2778081122 @default.
• W2157385885 hasConcept C2780942790 @default.
• W2157385885 hasConcept C71924100 @default.
• W2157385885 hasConcept C86803240 @default.
• W2157385885 hasConcept C8891405 @default.
• W2157385885 hasConceptScore W2157385885C136449434 @default.
• W2157385885 hasConceptScore W2157385885C16005928 @default.
• W2157385885 hasConceptScore W2157385885C203014093 @default.
• W2157385885 hasConceptScore W2157385885C204232928 @default.
• W2157385885 hasConceptScore W2157385885C2777379352 @default.
• W2157385885 hasConceptScore W2157385885C2777673923 @default.
• W2157385885 hasConceptScore W2157385885C2778081122 @default.
• W2157385885 hasConceptScore W2157385885C2780942790 @default.
• W2157385885 hasConceptScore W2157385885C71924100 @default.
• W2157385885 hasConceptScore W2157385885C86803240 @default.
• W2157385885 hasConceptScore W2157385885C8891405 @default.
• W2157385885 hasFunder F4320335295 @default.
• W2157385885 hasIssue "6" @default.

• next